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This study was carried out in order to compare the relative bioavailability of two different 
formulations containing 400 mg of acetaminophen + 4 mg of phenylephrine hydrochloride + 4 mg 
of chlorpheniramine maleate, Test formulation (Cimegripe®) and Reference formulation (Resfenol®) 
in 84 healthy volunteers of both sexes under fasting conditions. The study was conducted in a single 
dose, randomized, open-label, crossover 3-way and partially replicated. The tolerability was evaluated 
by the monitoring of adverse events and vital signs, results of clinical and laboratory tests. Plasma 
concentrations were quantified by validated bioanalytical methods using the ultra-performance 











and Kel pharmacokinetic parameters were calculated from these obtained concentrations. The 90% 
confidence intervals were constructed for the ratio reference/test from the geometric average of the 
C
max
 and AUC parameters which were comprised between 80% and 125%. Only the C
max
 parameter 
of the phenylephrine was applied the scaled average bioequivalence due to the intraindividual 
coefficient of variation > 30% obtained, thus extending the acceptance limits of the interval. It can 
be concluded that the two formulations were bioequivalent in terms of rate and absorption extent and 
thus interchangeable.
Keywords: Acetaminophen. Phenylephrine. Chlorpheniramine. Bioequivalence. Partially replicated 
crossover. Ultra-high performance liquid chromatography. Mass spectrometry.
INTRODUCTION
Over-the-counter medications do not need a 
prescription in order to be bought, they stay at pharmacy 
and drugstore counters, making self-medication easier. 
In general, medicines for the treatment of common cold 
and flu symptoms are freely mass-marketed to all the 
population (Eccles, 2014).
Acetaminophen (paracetamol) is a non-steroidal 
anti-inflammatory drug (NSAID) belonging to the 
class of p-aminophenol derivatives, with analgesic and 
antipyretic activity (Kalantzi et al., 2006; Guzman et 
al., 2016). Its analgesic action consists in inhibiting the 
synthesis of prostaglandins inside the central nervous 
system (CNS), besides acting as a peripheral blocker of 
pain impulse generation. However, its antipyretic effect 
is due to the inhibition of the hypothalamic thermal 
regulation center, causing peripheral vasodilation, 
sweating and heat dissipation (Anderson et al., 1998; 
Sebben et al., 2010). It is a drug rapidly absorbed by 
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the gastrointestinal tract, and its absolute bioavailability 
ranges from 62% to 89%, reaching the maximum 
plasma concentration of about 0.17 to 1.2 hours after its 
intake. Acetaminophen is distributed in most tissues and 
its binding to plasma proteins is negligible at therapeutic 
concentrations. Its half-life elimination is reported 
between 1.0 to 4.3 hours (Kalantzi et al., 2006; Guzman 
et al., 2016).
Phenylephrine hydrochloride is an alpha-adrenergic 
agonist, being vasoconstriction, redistribution of local 
blood flow and reduction of nasal mucosa edema 
some of the main effects of these receptors activation, 
therefore it is indicated for the temporary relief of nasal 
congestion (Resfenol, 2014; Gelotte, Zimmerman, 
2015). The most peak plasma concentration is obtained 
from 0.5 to 2.0 hours after oral administration, then it is 
a quickly absorbed drug. It rapidly distributes itsellf into 
peripheral tissues and undergoes first-pass metabolism 
producing a biphasic pharmacokinetic profile. The half-
life elimination period is short, about 2.5 hours and the 
oral bioavailability is relatively low, about 38% (Gelotte, 
Zimmerman, 2015).
Chlorpheniramine maleate is an antihistamine 
that acts as the first generation H1 receptor antagonist, 
the most potent in the alkylamines group. Used 
as an antiallergic, it is slowly absorbed from the 
gastrointestinal tract, its peak plasma concentration is 
from 2.5 to 6.0 hours after oral administration. About 
70% of the chlorpheniramine present in the circulation 
is bound to plasma proteins, consequently it is widely 
distributed throughout the body (Resfenol, 2014). The 
half-life elimination reported in the literature ranges 
from 18 to 43 hours (Yasuda et al., 2002).
The combination of acetaminophen, phenylephrine 
and chlorpheniramine is often used as active ingredients 
in medications for the symptomatic treatment of flu 
and common cold due to its pharmacological activities 
described above (Eccles et al., 2014; Khoshayand et 
al., 2010; Picon et al., 2013). Although, they have been 
available for over 50 years and have been used by millions 
of people, the pharmacokinetic data for phenylephrine 
and chlorpheniramine have been limited or nonexistent 
(Atkinson et al., 2015, Gelotte, Zimmerman, 2015, 
Yasuda et al., 2002).
Bioequivalence was defined as the absence of a 
significant difference in the rate and extent to which 
the active ingredient or active moiety in pharmaceutical 
equivalents or pharmaceutical alternatives becomes 
available at the site of drug action when administered 
at the same molar dose under similar conditions in an 
appropriately designed study. Bioequivalents. Two 
pharmaceutical products are therapeutically equivalent 
if they are pharmaceutically equivalent and after 
administration in the same molar dose their effects, with 
respect to both efficacy and safety, will be essentially 
the same as can be derived from appropriate studies 
bioequivalence. Therapeutically equivalent drug 
products are interchangeable (Brasil, 2002). 
Pharmacokinetic parameters were calculated from 
the plasma concentrations of healthy volunteers at 
predetermined times and the analytes were quantified by 
ultra-high performance liquid chromatography coupled 
to tandem mass spectrometry (UPLC - MS/MS).
In Brazil, relative bioavailability tests are required 
for the registration of similar medicinal product which 
use the bioequivalence criterion. The drug that meets the 
requirements of pharmaceutical equivalence, dissolution 
profile, bioequivalence and quality is considered a 
therapeutic equivalent of the reference medicine and 
can be interchangeable with it, presenting the same 
performance in the body, with the same efficacy and 
safety (Brasil, 2003; Porta, Chang, Storpirtis, 2005).
Thus, the objective of this study was to evaluate 
the relative bioavailability/bioequivalence for the 
registration of the similar drug acetaminophen 400 mg + 
phenylephrine hydrochloride 4 mg + chlorpheniramine 
maleate 4 mg (Cimegripe®, test product) produced by 
Cimed Indústria de Medicamentos Ltda., Brazil versus 
acetaminophen 400 mg + phenylephrine hydrochloride 
4 mg + chlorpheniramine maleate 4 mg (Resfenol®, 
reference product), produced by Kley Hertz S.A. 
Indústria e Comércio, Brazil. Unlike the traditional 
(crossover 2x2) average bioequivalence, mostly used 
along the majority of studies of this nature, the proposed 
design is the 3x3 crossover with the replicated reference 
drug, such a design is applied well to drugs with high 
variability and is suitable for bioequivalence studies.
SUBJECTS AND METHODS
Subjects and Ethics
The study included healthy volunteers of both 
sexes, aged 18 to 49 years old (mean ± sd; 32.44 ± 8.51) 
and body mass index (BMI) between 18.75 and 29.62 kg/
m2 (mean ± SD, 24.34 ± 2.66). Volunteers were equality 
distributed among groups and the same number of men 
and women were used.
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The good health conditions of the volunteers were 
confirmed through an evaluation including medical case 
history, physical examination, vital signs measurements, 
anthropometric data, 12-lead electrocardiogram (ECG) 
and laboratory tests (hematology, biochemistry, urine 1, 
hepatitis B and C and HIV), as well as pregnancy testing 
for women.
Some of the exclusion criteria were reactions of 
hypersensitivity to drugs, clinically significant case 
history or presence of renal, pulmonary, neurological, 
psychiatric, hematological, cardiologic, endocrine, 
immunological and diseases neoplasms. The use of any 
medicine, including those sold without a prescription, 
could not be taken regularly for at least 14 days and even 
irregularly, within 7 days before the beginning of the 
first study period. The participation in any clinical study 
within six months prior to the study initiation, pregnancy 
or lactation, significant loss or blood donation in quantities 
higher than 450 mL, and alcohol and/or drug abuse also 
prevented the individuals participation in the study.
It was conducted in accordance with national 
and international standards and research guidelines 
involving human beings (ICH, 1996; Brasil, 1997; 
Brasil, 2013; Declaration of Helsinki, 2013).
The project was approved by the Ethical Committee 
of the Faculdade de Ciências Médicas Dr. José Antônio 
Garcia Coutinho da Universidade do Vale do Sapucaí, 
Pouso Alegre, Brazil (approval number: 748,540). After 
explaining the nature and purpose of the research, the 
volunteers provided written informed consent before 
starting the study. All study stage were carried out by 
Instituto Cláudia Marques de Pesquisa e Desenvolvimento 
Ltda. (ICMP&D), Pouso Alegre, Brazil.
Study design
The study planning was developed to include 
healthy volunteers of both sexes under fasting conditions, 
wherein the drugs administration were in a single dose, 
randomized, open-label, crossover with 2 treatments, 3 
sequences, 3 periods and partially replicated. The study 
design was 3x3 with the reference replicated medication, 
generating the following sequences: RTR, RRT and TRR.
The administration of two capsules of each product 
(test and reference) was initiated, regarding the list of 
randomization, at 07:00 am, after a fasting period of 10 
hours. No food was allowed for four hours after the dose 
intake. Subjects received standardized meals at 4 hours 
(lunch), 8 hours (snack) and 10 hours (supper) after 
the drug intake in each treatment. The volunteers did 
not have alcoholic beverage, coffee, drinks containing 
xanthines, or foods outside the prescribed diet during 
the study. Each confinement period lasted 26 hours 
on average and the washout period between these 
administrations was of seven days. 
Tolerability
For tolerability monitoring purposes, the volunteers 
were supervised throughout the study in order to 
detect adverse events. The volunteers were questioned 
about the adverse events occurrence at the time of 
confinement, prior to the products administration under 
investigation and during the study follow-up in each 
period. In addition, all subjects were advised to report 
any adverse event occurrence immediately to the team. 
During hospitalizations, blood pressure, pulse and body 
temperature were monitored at predefined times. At the 
end of the study, the results of the laboratory tests (except 
serology) and ECG were repeated and evaluated during 
the medical appointment in a way that was comparable 
to those obtained during the volunteer selection phase. 
Sample collection and processing
The definition of the number of collections and the 
interval from obtaining the blood samples to constructing 
the concentration curves versus time were based on the 
pharmacokinetic profile of the drugs: acetaminophen, 
phenylephrine hydrochloride and chlorpheniramine 
maleate. We used the collection schedule truncated in 
72 hours for the chlorpheniramine drug that has half-
life greater than 24 hours. Before the administration of 
the investigational products, baseline blood sampling 
was performed and blood samples were collected at 
the following times: 0.16, 0.33, 0.50, 0.66, 0.83, 1.0, 
1.25, 1.50, 1.75, 2.0, 2.33, 2.66, 3.0, 3.50, 4.0, 5.0, 6.0, 
8.0, 10.0, 12.0, 14.0, 24.0, 48.0 and 72.0 hours in 7.5 ml 
tubes containing heparin as anticoagulant. Plasma was 
immediately separated by centrifugation at 3500 rpm 
for 10 minutes at 4 ºC and stored in cryogenic tubes at 
-70 ºC (ultra-freezer) until its analysis time.
Plasma samples analysis
Three different bioanalytical methods were 
developed and validated according to RDC nº 27/12 
(ANVISA, 2012) for the plasma quantification of 
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the active components of acetaminophen (AMP), 
phenylephrine (PHEN) and chlorpheniramine (CHL) 
by liquid chromatography coupled to tandem mass 
spectrometry based on previously published methods 
(Feng et al., 2013; Li et al., 2010; Moreno et al., 2010; 
Ptáček et al., 2007; Sebben et al., 2010).
The analytical run contained samples of quality 
controls (QCs), calibration standards, and unknown 
samples from one or more study volunteers. The samples 
analysis for each analyte in the biological matrix was 
completed within the time period for which the stabilities 
were determined. All samples from the same volunteer 
were analyzed in the chromatographic run. In the routine 
use of the validated analytical method, its precision 
and accuracy were regularly monitored through QCs 
samples to ensure satisfactory performance continuity. 
The QCs samples were incorporated at appropriate 
intervals depending on the total number of run samples, 
always on an equal number of replicates of each high, 
middle and low levels (HQC, MQC and LQC).
Chromatographic analyses were performed on a liquid 
chromatograph of the Acquity UPLC System (Waters 
Corporation, MA, USA) coupled to a mass spectrometer 
(MS/MS), Mass Spectrometer Acquity TQ Detector 
(Waters Corporation, MA, USA) for acetaminophen 
and chlorpheniramine drugs and coupled to the Xevo 
TQS equipment (Waters Corporation, MA, USA) for 
phenylephrine analysis. An electrospray ionization (ESI) 
with multiple reaction monitoring (MRM) mode was used 
to monitor the precursor-product ion transitions and triple 
quadrupole (Tandem Quadrupole) analyzer using the 
MassLynx ™ software (Waters Corporation, MA, USA) 
in version 4.1. Table I shows the methods description used 
for the samples analysis.
TABLE I - Bioanalytical methods for the drugs acetaminophen, phenylephrine and chlorpheniramine
ITENS AMP PHEN CHL
Internal standard 50 µL venlafaxine (50 µg/mL) 25 µL propranolol (10 ng/mL)
25 µL bromodiphenhydramine 
(300 ng/mL)
Biological matrix 100 µL of plasma 500 µL of plasma 200 µL of plasma
Extraction 1.50 mL ethyl acetate 
1.25 mL of ethyl ether: 
dichloromethane (70:30; v:v)
1.00 mL of ethyl acetate: 
hexane (1:1; v:v)
Column
Waters Acquity UPLC 
BEH C8 1.7 µm 
(2.1 x 50.0) mm
Waters Acquity Cortecs UPLC 
HILIC 1.6 µm (2.1 x 75.0) mm
Waters Acquity UPLC 
BEH C18 1.7 µm
(2.1 x 50.0) mm
Guard cartridge
VanGuard UPLC BEH C8 1,7 µm 
(2.1 x 5.0) mm
VanGuard UPLC BEH 
HILIC 1.7 µm
(2.1 x 5.0) mm
VanGuard UPLC BEH C18 1.7 µm
(2.1 x 5.0) mm
Oven temperature 35°C ± 5 ºC 30°C ±5 ºC 35°C ± 5 ºC
Transition
AMP 152.10 > 110.10
IS 278.24 > 121.07
PHEN 168.13 > 150,10
IS 260.10 > 116,14
CHL 275.16 > 230.10
IS 334.10 > 165.15
Wash solution
Strong Needle Wash: methanol 
: Ultrapure water (90:10, v/v)
Weak Needle Wash: metanol: 
Ultrapure water (70:30, v/v) + 
0,05% ammonium hydroxide 
Seal Wash in: Ultrapure Water 
: methanol ((90:10, v/v)
Strong Needle Wash: acetonitrile
Weak Needle Wash: acetonitrile: 
acetonitrile: 20 mM ammonium 
formate solution + 0.1% 
acetic Acid (90:10, v/v)
Seal Wash in:Ultrapure Water 
: methanol (90:10, v/v)
Strong Needle Wash: methanol
Weak Needle Wash: methanol: 
Ultrapure Water(80:20, v/v)
Seal Wash in: Ultrapure Water 
: methanol (90:10, v/v)
(continuing)
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TABLE I - Bioanalytical methods for the drugs acetaminophen, phenylephrine and chlorpheniramine
ITENS AMP PHEN CHL
Mobile fase
methanol (HPLC level) : 
Ultrapure water + 0,05% de 
ammonium hydroxide (70:30, 
v/v), separate channels 
acetonitrile (HPLC level): 
acetonitrile (HPLC grade): 
20 mM ammonium formate 
solution + 0.1% acetic acid 
(89:11, v/v), separate channels 
methanol (HPLC level) : 10mM 
ammonium formate solution 
(80:20, v/v), separate channels 
Flow of mobile fase 0.300 mL/min 0.350 mL/min 0.250 mL/min
Injection volume 2.0 µL 7.5 µL 4.0 µL
Auto-injector 
temperature
5°C ± 4 ºC 5°C ± 3 ºC 10°C ± 3 ºC










300 ng/mL 50 pg/mL 400 pg/mL
Low quality control 900 ng/mL 150 pg/mL 1200 pg/mL
Mediam quality 
control
7500 ng/mL 10000 pg/mL 15000 pg/mL
High quality 
control
11500 ng/mL 1500 pg/mL 22500 pg/mL
AMP: acetaminophen; PHEN: phenylephrine; CHL: chlorpheniramine; IS: internal standard. 
Pharmacokinetic and Statistical Analysis
All pharmacokinetic and statistical analyses were 
performed using Phoenix WinNonlin 6.4 software 
version (Pharsigh Corporation, NC, USA). The following 
pharmacokinetic parameters were determined after the 
quantification of plasma concentrations performed in 




 = Maximum plasma concentration detected 
after each treatment (Test and Reference).
T
max




 = Area under the concentration curve versus 




 = Area under the concentration curve 
versus time from zero to infinity.
T
1/2 
= Terminal elimination half-life..
K
el
 = Constant rate of terminal phase.
The pharmacokinetic parameters employed in the 
relative bioavailability/bioequivalence analysis were 
Cmax and AUC. Cmax was obtained directly from the 
plasma concentration versus time curve and the AUC 
was calculated using conventional trapezoidal rule. 
The traditional criterion of average bioequivalence 
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was used, thus, a 90% confidence interval (CI) was 
constructed for the difference of log-transformed data 
averages of test drugs and reference, for Cmax and 
AUC0-t parameters. The antilogarithm of the obtained 
CI constituted the 90% CI for geometric averages ratio 
of these parameters: (Cmax test/Cmax ref and AUC0-t 
test/AUC0-t ref). The formulations were considered 
statistically bioequivalent if these ranges were between 
80% and 125% limits.
The scaled bioequivalence average can be applied 
only to highly variable drugs, where the intraindividual 
coefficient of variation is greater than 30% (CVwr > 
30%), as it was the case with phenylephrine. Due to 
the lack of information regarding chlorpheniramine 
drug the stepped bioequivalence average could also be 
applied to this drug as long as the conditions established 
above were satisfied. According to the World Healthy 
Organization (WHO, 2017) for highly variable drugs, it 
is recommended a three-way partial replication, where 
the reference drug is administered twice, and to use the 
scaled bioequivalence technique that allows the IC of 
90% for Cmax parameter if high intra-subject variability 
for Cmax after replicate administrations of the reference 
product was > 30%. If this were the case, the acceptance 
criteria for Cmax could be extended to the maximum of 
69.84 - 143.19%.
Thus, a 3x3 design (three periods and three 
sequences) with the replicated reference product was 
generated, providing the sequences: Reference/Test/
Reference (RTR), Reference/Reference/Test (RRT) and 
Test/Reference/Reference (TRR).
The widening extent of the interval for Cmax is 
defined based on the intra-subject variability seen in 
the bioequivalence study using scaled bioequivalence 
average according to [U, L] = exp [± k sWR], where 
U is the upper limit of the acceptance range, L is the 
lower limit of the acceptance range, k is the regulatory 
constant set to 0.760 and sWR is the standard deviation 




The study was completed with 77 volunteers (38 
men and 39 women), which are part of the statistical 
analyses. Of the seven volunteers who dropped out 
of the study, four did not attend the second period of 
confinement and three did not attend the third period for 
personal reasons.
The most common adverse event reported by 
11 volunteers was headache. Only 3.77% of the 
events reported by the volunteers were classified 
with possible relation with the drugs under study. Of 
the reported adverse events, 52.83% occurred in the 
reference drug administration and 47.17% in the test 
formulation administration, of which 86.79% were of 
mild intensity.
Both formulations were well tolerated, no serious 
adverse events were reported or observed during the 
study. No clinical and laboratory parameters presented 
clinically relevant alterations following physical 
examination, vital signs, electrocardiogram and 
laboratory tests.
Method validation and plasma samples analysis
We used three different quantification methods, one 
for each drug. The methods were validated by evaluating 
selectivity, linearity, accuracy, precision, short and 
long stabilities and matrix effect. In order to determine 
precision and accuracy of the methods, five replicates of 
each QCs sample were evaluated. In this study short and 
long stability tests under ANVISA requirements were 
performed. The range of the coefficients of variation 
(CVs) of the data set was used to express the results 
obtained. Table II summarizes the results. 
The concentration calculations of the volunteers’ 
samples were performed according to the calibration 
curve constructed by acetaminophen, phenylephrine 
and chlorpheniramine analytes and obtained using 
MassLynx™ software (Waters Corporation, MA, USA) 
from the calibration standards. These functions are 
calculated by the ratio between the peak areas of the 
analytes under study and respective peaks of internal 
standards. 
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TABLE II - Parameters obtained in validations of the bioanalytical methodos for determination acetaminophen, phenylephrine 
and chlorpheniramine
Parameters AMP PHEN CHL
Linearity 300 – 15000 ng/mL 50 – 20000 pg/mL 400 – 300000 pg/mL
Straigh-line equation y = 0.000323x + 0.0143 y = 0.000193x + 0.00284 y = 0.0000606x + 0.00368
Linear correlation coefficient r = 0.998363 r = 0.999450 r = 0.999009
Precision intra-day 0.8 – 10.5% 0.5 – 12.9% 1.2 – 7.8%
Precision inter-day 2.3 – 6.9% 2.7 – 8.5% 3.2 – 6.0%
Accuracy intra-day – 9.7 – 11.8% – 16.1 – 0.4% – 14.5 – 6.3
Accuracy inter-day – 9.2 – 6.6% – 8.1 – 2.0% – 10.0% – 3.8%
Short-term stability
Autosampler samples, 12h at 5°C
– 13.6 – 7.0%
(12h at 5°C)
– 8.3 – 1.0% – 3.9 – 0.4
Room sample, 6 h at 25°C – 11.0 – 9.8% – 13.0 – 3.8% – 6.6 5.3
4 Freeze-thaw cycles – 11.7 – 6.9% – 13.0 – 5.2% – 4.3 4.5
Long-term stability
Plasma sample (storage at -70 °C) 
– 11.0 – 6.9%
(122 days)
– 13% – 2.8%
(70 days)
– 4.3 – 6.0
(107 days)
FMN (Normalized matrix 
factor for analyte and IS)
AMP: acetaminophen; phen: 
phenylephrine; Chl: chlorpheniramine
3.5% 10.0% 5.1%
Pharmacokinetic parameters and 
Bioequivalence evaluation
The a verage plasma concentration-time profiles of 
77 healthy volunteers in single dose oral administration 
with 800 mg of acetaminophen, 8 mg of phenylephrine 
and 8 mg of chlorpheniramine in gel capsules (two) 
are shown in Figures 1A, 1B and 1C, respectively. The 
curves demonstrated similares absorption, distribution 
and elimination for both products: reference (R) 
and test (T). 
The main pharmacokinetics parameters were 
summarized in Table III. Table IV reports the confidence 
intervals for the test/reference ratio (90% CIs) of log-
transformed Cmax, AUC0-t, AUC0-inf.
The CVwr for phenylephrine in Cmax parameter 
obtained in the study was equal to 57.29%, and thus it was 
applied to scaled bioequivalence. Table V shows the ratio 
between the geometric averages, confidence intervals, 
variation coefficient of the reference medication and 
the acceptance limits extension for phenylephrine in 
Cmax parameter. 
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FIGURE 1 - Average plasma concentrations versus time profile obtained after a single oral administration of drugs containing 
acetaminophen (A), maleate of phenylephrine (B) and chlorpheniramine (C) in healthy volunteers.
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TABLE III - Pharmacokinetics parameters of acetaminophen, phenylephrine and chlorpheniramine after single dose in healthy 

















(mean ± SD) (mean ± SD) (mean ± SD)
C
max
 (ng/mL) 8116.689 ± 236.754 8347.459 ± 332.199 3.271 ± 0.195 3.470 ± 0.247 13.630 ± 0.318 13.359 ± 0.414
T
max
 (h) 1.314 ± 0.060 1.203 ± 0.082 0.779 ± 0.037 0.736 ± 0.045 3.024 ± 0.119 2.949 ± 0.150
AUC
0-t 
(ng*h/mL) 27367.318 ± 688.355 27454.247 ± 903.326 2.054 ± 0.079 2.157 ± 0.095 313.358 ± 9.652 309.393 ± 12.690
AUC
0-inf 
(ng*h/mL) 28918.267 ± 710.189 28992.062 ± 941.982 2.245 ± 0.083 2.385 ± 0.101 374.998 ± 16.427 368.447 ± 20.098
T ½ (h) 2.598 ± 0.061 2.667 ± 0.083 1.835 ± 0.142 2.379 ± 0.396 21.961 ± 0.813 22.178 ± 1.099
K
el
0.286 ± 0.006 0.277 ± 0.008 0.618 ± 0.032 0.552 ± 0.037 0.036 ± 0.001 0.035 ± 0.001
AMP: acetaminophen; PHEN: phenylephrine; CHL: chlorpheniramine; R: product reference; T: product test; SD: standard 
deviation
TABLE IV - 90% Confidence intervals for the log-transformed parameters ratio test/reference (n=77)
Parameters
AMP PHEN CHL
Ratio % 90% CI Ratio% 90% CI Ratio % 90% CI
C
max
103.25 96.93 - 109.98 111.88 98.53 - 127.04 98.16 94.82 - 101.62
AUC
0-t
100.81 98.65 - 103.03 107.29 101.36 - 113.57 99.37 95.36 - 103.55
AUC
0-inf
100.63 98.58 – 102.73 108.15 102.41 - 114.22 99.65 94.68 - 104.88
AMP: acetaminophen; PHEN: phenylephrine; CHL: chlorpheniramine; CI: Confidence interval
TABLE V - Ratio between geometric means, confidence intervals, reference coefficient of variation and extension of the 











111.88 98.53 127.04 57.29 69.84 143.19
ABE: Average Bioequivalence; CI: Confidence interval; CV
WR
: coeficient of variation intra-subject of the reference product
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DISCUSSION
The efficacy, safety and quality evidences of 
over-the-counter drugs in Brazil aim to ensure that 
individuals who choose self-medication have access to 
safe and effective medication.
The results obtained by Picon et al., (2013) suggest 
that the fixed dose combination of acetaminophen, 
phenylephrine and chlorpheniramine may be an effective 
and safe alternative for the symptomatic treatment of 
common cold and flu. Combination products for multiple 
symptoms relief containing various active ingredients 
provide a safe, effective, economical and convenient 
way of treating multiple symptoms when used according 
to instructions. Both formulations were well tolerated 
and all volunteers who completed the study had no 
significant adverse events.
In the present study, we used three ultra-
performance liquid chromatography methods coupled 
to mass spectrometry (UPLC - MS/MS) to quantify 
acetaminophen, phenylephrine and chlorpheniramine 
analytes in plasma and allowed us to evaluate the 
pharmacokinetic profiles of the active principles in 
bioequivalence studies. The results of the methods 
validation indicated that the selectivity, precision, 
accuracy, short term stability, long term stabilitity and 
the methods matrix effect obeyed the criteria required 
by Brazilian law for bioanalysis application. 
The analytical methods were simple and fast 
and no interferences were found from endogenous 
components of plasma or other sources. It can be 
seen that the coefficients of variation of the intra-day 
and inter-day precision did not exceed 15.0%. In the 
case of accuracy intra and inter-day, the values were 
within -15.0 and 15.0%. Except for phenylephrine 
which had the CV of -16.1% in the intra-assay accuracy 
because the reported values included the lower limit 
of quantification quality control (LLOQ). The LLOQ 
should not deviate by more than 20%. Therefore no 
stability related problems were found during sample 
analyses. No statistical differences were found in 
slope or intercept between human plasma samples of 
volunteers. The bioanalytical methods can also be used 
for pharmacokinetic and bioavailability studies. 
The plasma concentrations of the samples were 
derived from the linear regression equation of the 
line using the 1/x2 weighting, since it presented the 
smallest sum of the nominal values relative errors of 
the calibration standards versus values obtained by their 
curve equation. The use of this mathematical model was 
decided due to the extensive range of concentrations 
used in the samples quantification. This model is the 
simplest and best accommodates the inherent variations 
to the experimental method.
The pharmacokinetic parameters calculated for 
both the test and the reference formulations were 
not significantly different, reflecting the comparable 
pharmacokinetic characteristics of two formulations. 
The parameters Tmax, T1/2, Cmax and AUC0-t for 
the three drugs which make up the formulations are in 
accordance with those established in the drug reference 
paper and in the consulted literature (Kalantzi et al., 
2006; Ptáček et al., 2007; Lou et al., 2010; Moreno et 
al., 2010, Atkinson et al., 2015; Gelotte, Zimmerman, 
2015). Observing the statistical results of phenylephrine 
hydrochloride, it is clear, for the Cmax parameter, 
that the upper limit of the 90% confidence interval 
is outside the 80% - 125% limits. With the use of 
a suitable design, for this study the RRT, RTR and 
TRR partially replicated and as the reference product 
variation coefficient was superior to 30% (CVwr = 
57.29%, obtained in the study in question) the scaled 
bioequivalence could be applied. Thus, the acceptance 
limits for this parameter were 69.84% - 143.19%. The 
statistical treatments adopted for it were suitable to 
guarantee the reliability of the bioequivalence results 
among the formulations. All 90% confidence intervals 
for Cmax and AUC pharmacokinetic parameters are 
within the limits previously established in protocol.
CONCLUSION
The drugs acetaminophen, phenylephrine and 
chlorpheniramine were evaluated in both formulations 
according to the results obtained. The test formulation 
is statistically bioequivalent to the reference formulation 
in terms of rate and extent of absorption and therefore 
interchangeable.
ACKNOWLEDGEMENTS
This study supported was provided by Cimed 
Indústria de Medicamentos Ltda., Pouso Alegre, MG, 
Brazil. 
The authors have no conflicts of interests towards 
the content of this study. 
Evaluation of the bioequivalence of two formulations containing the combination of 400 mg of acetaminophen (paracetamol), 4 mg of phenylephrine  
and 4 mg of chlorpheniramine in capsules: open-label, three-way crossover study, partially replicated in healthy volunteers of both sexes
Braz. J. Pharm. Sci. 2020;56: e17836 Page 11/12
REFERENCES
Anderson BJ, Holford NHG, Woolard GA, Chan PLS. 
Paracetamol plasma and cerebrospinal fluid pharmacokinetics 
in children. Br J Clin Pharmacol. 1998;46(3):237-243.
Atkinson HC, Stanescu I, Salem II, Potts AL, Anderson 
BJ. Increased bioavailability of phenylephrine by co-
administration of acetaminophen: Results of four open-label, 
crossover pharmacokinetic trials in healthy volunteers. Eur J 
Clin Pharmacol. 2015;71(2):151-8.
Brasil. Agência Nacional de Vigilância Sanitária. Manual 
de Boas Práticas em Biodisponibilidade/Bioequivalência. 
Volume I. Agência Nacional de Vigilância Sanitária. 
Brasília, 2002. 
Brasil. Agência Nacional de Vigilância Sanitária. Resolução 
n° 134, de 29 de maio de 2003. Dispõe sobre a adequação dos 
medicamentos já registrados. Diário Oficial da União 02 jun 
2003; Seção 1. 
Brasil. Agência Nacional de Vigilância Sanitária. Resolução 
n° 27, de 17 de maio de 2012. Dispõe sobre os requisitos 
mínimos para a validação de métodos bioanalíticos 
empregados em estudos com fins de registro e pós-registro de 
medicamentos. Diário Oficial da União 22 mai 2012; Seção 1.
Brasil. Conselho Nacional de Saúde. Resolução nº 466, de 
12 de dezembro de 2012. Aprova as diretrizes e normas 
regulamentadoras de pesquisas envolvendo seres humanos. 
Diário Oficial da União 13 jun 2013; Seção 1. 
Brasil. Conselho Nacional de Saúde. Resolução nº 251, de 7 
de agosto de 1997. Aprova normas de pesquisa envolvendo 
seres humanos para a área temática de pesquisa com novos 
fármacos, medicamentos, vacinas e testes diagnósticos. 
Diário Oficial da União 07 ago 1997; Seção 1.
Declaration of Helsinki - Ethical Principles for Medical 
Research Involving Human Subjects. 64th WMA General 




Eccles R, Fietze I, Rose U-B. Rationale for Treatment of 
Common Cold and Flu with Multi-Ingredient Combination 
Products for Multi-Symptom Relief in Adults. Open J Respir 
Dis. 2014;4(3):73-82.
Feng S, Zhao Q, Jiang J, Hu P. Determination of phenylephrine 
in human plasma using ultra-performance liquid 
chromatography-tandem mass spectrometry. J Chromatogr B 
Anal Technol Biomed Life Sci. 2013;915-916:28-32.
Gelotte CK, Zimmerman BA. Pharmacokinetics, Safety, and 
Cardiovascular Tolerability of Phenylephrine HCl 10, 20, 
and 30 mg After a Single Oral Administration in Healthy 
Volunteers. Clin Drug Investig. 2015;35(9):547-58.
Guzman NAN, Molina DR, Núñez BF, Soto-Sosa JC, Abarca 
JEH. Bioequivalence and pharmacokinetic evaluation study 
of acetaminophen vs. acetaminophen plus caffeine tablets in 
healthy mexican volunteers. Drugs R D. 2016;16:339-345. 
International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human 
Use. ICH Harmonised Tripartite. Guideline for Good Clinical 
Practice; 1996. [citad 2016 Mar 8]. Available from: http://
www.ich.org/fileadmin/Public_Web_Site/ICH_Products/
Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf.
Kalantzi L, Reppas C, Dressman JB, Amidon GL, 
Junginger HE, Midha KK, et al. Biowaiver monographs for 
immediate release solid oral dosage forms: Acetaminophen 
(Paracetamol). J Pharm Sci. 2006;95(1):4-14.
Khoshayand MR, Abdollahi H, Ghaffari A, Shariatpanahi 
M, Farzanegan H. Simultaneous spectrophotometric 
determination of paracetamol, phenylephrine and 
chlropheniramine in pharmaceuticals using chemometric 
approaches. Daru. 2010;18(4):292-7.
Li H, Zhang C, Wang J, Jiang Y, Fawcett JP, Gu J. Simultaneous 
quantitation of paracetamol, caffeine, pseudoephedrine, 
chlorpheniramine and cloperastine in human plasma by 
liquid chromatography-tandem mass spectrometry. J Pharm 
Biomed Anal. 2010;51(3):716-22.
Lou H gang, Yuan H, Ruan Z rong, Jiang B. Simultaneous 
determination of paracetamol, pseudoephedrine, dextrophan 
and chlorpheniramine in human plasma by liquid 
chromatography-tandem mass spectrometry. J Chromatogr B 
Anal Technol Biomed Life Sci 2010;878:682-8.
Moreno RA, Oliveira-Silva D, Sverdloff CE, Borges BC, 
Galvinas PAR, Astigarraga RB, et al. Determination of 
chlorpheniramine in human plasma by HPLC-ESI-MS/
MS: Application to a dexchlorpheniramine comparative 
bioavailability study. Biomed Chromatogr. 2010;24(7): 
774-81.
Picon PD, Costa MB, da Veiga Picon R, Fendt LCC, Suksteris 
ML, Saccilotto IC, et al. Symptomatic treatment of the 
common cold with a fixed-dose combination of paracetamol, 
chlorphenamine and phenylephrine: a randomized, placebo-
controlled trial. BMC Infect Dis. 2013;13:556.
Porta V, Chang KH, Storpirtis S. Evaluation of the 
bioequivalence of capsules containing 150 mg of fluconazole. 
Int J Pharm. 2005;288(1):81-6.
Alessandra Ferreira dos Santos, Quevellin Alves dos Santos, Carlos Eduardo Melo Correa, Edvaldo Capobiango Coelho
Page 12/12 Braz. J. Pharm. Sci. 2020;56: e17836
This is an open-access article distributed under the terms of the Creative Commons Attribution License. 
Ptáček P, Klíma J, Macek J. Development and validation of 
a liquid chromatography–tandem mass spectrometry method 
for the determination of phenylephrine in human plasma and 
its application to a pharmacokinetic study. J Chromatogr B 
2007;858:263–8.
Resfenol: paracetamol, maleato de clorfeniramina, cloridrato 
de fenilefrina [bula de medicamento na internet]. Responsável 
técnico Marcia Cruz Valiati. Porto Alegre: Kley Hertz 
Farmacêutica S.A. [citad 2014 Jun 23]. Available from: http://
www.anvisa.gov.br/datavisa/fila_bula/frmVisualizarBula.
asp?pNuTransacao=15353142016&pIdAnexo=3300897. 
Sebben VC, Lugoch RDW, Schlinker CS, Arbo MD, 
Vianna RL. Validação de metodologia analítica e estudo de 
estabilidade para quantificação sérica de paracetamol. J Bras 
Patol E Med Lab. 2010;46(2):143-8. 
World Health Organization. WHO. Multisource (generic) 
pharmaceutical products: guidelines on registration 
requirements to establish interchangeability. In: WHO 
Expert Committee on Specifications for Pharmaceutical 
Preparations. Fifty-first report of the WHO Expert Committee 
on specifications for pharmaceutical preparations. Geneva: 
World Health Organization, 2017.
Yasuda SU, Zannikos P, Young AE, Fried KM, Wainer IW, 
Woosley RL. The roles of CYP2D6 and stereoselectivity in 
the clinical pharmacokinetics of chlorpheniramine. Br J Clin 
Pharmacol. 2002;53(5):519-25.
Received for publication on 19th December 2017
Accepted for publication on 11st March 2019
